OPKO Health, Inc. to Post FY2024 Earnings of ($0.35) Per Share, Zacks Research Forecasts (NASDAQ:OPK)

OPKO Health, Inc. (NASDAQ:OPK) – Equities researchers at Zacks Research lifted their FY2024 EPS estimates for OPKO Health in a research report issued on Monday, April 15th. Zacks Research analyst I. Bandyopadhyay now expects that the biotechnology company will post earnings of ($0.35) per share for the year, up from their prior forecast of ($0.36). The consensus estimate for OPKO Health’s current full-year earnings is ($0.33) per share. Zacks Research also issued estimates for OPKO Health’s Q2 2025 earnings at ($0.05) EPS, Q3 2025 earnings at ($0.05) EPS, Q4 2025 earnings at ($0.05) EPS, FY2025 earnings at ($0.21) EPS, Q1 2026 earnings at ($0.05) EPS and FY2026 earnings at ($0.12) EPS.

OPKO Health (NASDAQ:OPK) last posted its quarterly earnings results on Tuesday, February 27th. The biotechnology company reported ($0.09) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.09). The business had revenue of $181.90 million during the quarter, compared to the consensus estimate of $177.53 million. OPKO Health had a negative net margin of 21.76% and a negative return on equity of 12.69%. OPKO Health’s revenue for the quarter was down 1.9% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.11) earnings per share.

Other equities research analysts also recently issued reports about the stock. Barrington Research reissued an “outperform” rating and set a $1.50 price target on shares of OPKO Health in a research note on Monday, April 1st. Piper Sandler reaffirmed an “overweight” rating and issued a $5.00 target price on shares of OPKO Health in a research note on Monday, April 1st. HC Wainwright reaffirmed a “buy” rating and issued a $3.00 target price on shares of OPKO Health in a research note on Wednesday, April 3rd. Finally, StockNews.com downgraded shares of OPKO Health from a “hold” rating to a “sell” rating in a research note on Friday, March 1st.

OPKO Health Trading Down 1.6 %

OPK opened at $1.23 on Wednesday. The company has a debt-to-equity ratio of 0.15, a current ratio of 1.55 and a quick ratio of 1.22. The company has a market cap of $857.30 million, a price-to-earnings ratio of -4.92 and a beta of 1.82. The firm has a 50 day simple moving average of $1.07 and a 200 day simple moving average of $1.24. OPKO Health has a fifty-two week low of $0.85 and a fifty-two week high of $2.24.

Insider Activity

In related news, CEO Phillip Md Et Al Frost purchased 500,000 shares of OPKO Health stock in a transaction dated Monday, March 18th. The stock was bought at an average price of $0.87 per share, for a total transaction of $435,000.00. Following the completion of the acquisition, the chief executive officer now directly owns 210,968,225 shares of the company’s stock, valued at $183,542,355.75. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink. In related news, CEO Phillip Md Et Al Frost purchased 500,000 shares of OPKO Health stock in a transaction dated Monday, March 18th. The stock was bought at an average price of $0.87 per share, for a total transaction of $435,000.00. Following the completion of the acquisition, the chief executive officer now directly owns 210,968,225 shares of the company’s stock, valued at $183,542,355.75. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Richard M. Krasno purchased 30,000 shares of OPKO Health stock in a transaction dated Monday, January 29th. The stock was bought at an average price of $0.99 per share, with a total value of $29,700.00. Following the acquisition, the director now directly owns 103,333 shares of the company’s stock, valued at $102,299.67. The disclosure for this purchase can be found here. Insiders purchased 4,630,000 shares of company stock worth $4,422,700 over the last quarter. 47.26% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in OPK. State Street Corp boosted its holdings in OPKO Health by 56.7% during the first quarter. State Street Corp now owns 27,688,831 shares of the biotechnology company’s stock worth $95,250,000 after purchasing an additional 10,014,088 shares during the last quarter. Millennium Management LLC boosted its holdings in OPKO Health by 318.6% during the second quarter. Millennium Management LLC now owns 7,390,435 shares of the biotechnology company’s stock worth $18,698,000 after purchasing an additional 5,624,866 shares during the last quarter. Invesco Ltd. boosted its holdings in OPKO Health by 300.4% during the third quarter. Invesco Ltd. now owns 5,164,180 shares of the biotechnology company’s stock worth $8,263,000 after purchasing an additional 3,874,519 shares during the last quarter. Renaissance Technologies LLC boosted its holdings in OPKO Health by 848.7% during the second quarter. Renaissance Technologies LLC now owns 3,890,172 shares of the biotechnology company’s stock worth $9,842,000 after purchasing an additional 3,480,129 shares during the last quarter. Finally, Norges Bank acquired a new position in OPKO Health during the fourth quarter worth $4,042,000. Institutional investors and hedge funds own 64.63% of the company’s stock.

About OPKO Health

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.